CLINICAL DRUG DEVELOPMENT SL
Company details
- Active NIF/CIF: B66958943
-
-
-
-
Address: Passeig de la Reina Elisenda de Montcada, 13, 08034 Barcelona, España See in map
-
-
Featured products:
More information on CLINICAL DRUG DEVELOPMENT SL
-
15/07/2024 | BORME act no.: 313857 | Register: BARCELONARevocaciones
-
15/07/2024 | BORME act no.: 313857 | Register: BARCELONANombramientos
-
20/09/2021 | BORME act no.: 422316 | Register: BARCELONAAmpliación de capital
-
20/09/2021 | BORME act no.: 422316 | Register: BARCELONAOtros conceptos
-
15/03/2017 | BORME act no.: 118442 | Register: BARCELONAConstitución
-
15/03/2017 | BORME act no.: 118442 | Register: BARCELONANombramientos
-
15/03/2017 | BORME act no.: 118442 | Register: BARCELONAOtros conceptos
Other information
The CIF of CLINICAL DRUG DEVELOPMENT SL is B66958943 and its current business status is active. Its economic sector is within the CNAE 7219 - Otra investigación y desarrollo experimental en ciencias naturales y técnicas. Its SIC classification is -.
CLINICAL DRUG DEVELOPMENT SL employs approximately Between 1 and 9 employees and generates an annual turnover of less than 2 million euros. The company is registered in the Mercantile Registry of Barcelona. To date, it has 3 registration charges. Its most recent announcement in the Borme was published on 15/07/2024 and its last deposit of ordinary annual accounts corresponds to the year 2022.
You can access the contact information of CLINICAL DRUG DEVELOPMENT SL, such as the telephone number, postal address, and website, in the Company Data section.
If you wish to obtain more information about CLINICAL DRUG DEVELOPMENT SL, you can review one of our available financial reports, the Annual Accounts of the company, or check if it has any registered payment incidents in the RAI delinquency file.
The financial, commercial, and legal information of CLINICAL DRUG DEVELOPMENT SL comes from official data sources and is automatically updated every day.
Do you want to know more about CLINICAL DRUG DEVELOPMENT SL??
Find out more about this company by consulting these reports: